cat no | io1035, io1036
ioMicroglia TREM2 R47H/R47H are opti-ox™ precision reprogrammed microglia carrying a genetically engineered homozygous R47H mutation in the TREM2 gene encoding the triggering receptor expressed on myeloid cells 2 protein. The TREM2 R47H mutation has been linked with increased risk of late-onset Alzheimer's disease (AD).
These cells offer a functional, rapidly maturing, and disease relevant system to study the role of the TREM2 R47H mutation in late-onset AD, alongside a genetically matched wild-type control.
Two clones are available, all genetically matched to the wild type control, ioMicroglia™. The disease model cells and the wild-type control offer a physiologically relevant model to investigate the impact of the TREM2 R47H mutation on cellular and molecular mechanisms and function in late-onset AD.
Confidently investigate your phenotype of interest across multiple clones with our disease model clone panel. Detailed characterisation data (below) and bulk RNA sequencing data (upon request) help you select specific clones if required.
per vial
A maximum number of 20 vials applies. If you would like to order more than 20 vials, please contact us at orders@bit.bio.
Making True Comparisons
Pair the ioDisease Model Cells with the genetically matched wild-type ioMicroglia to directly investigate the effect of the mutant TREM2 protein on late-onset AD.
Quick
Rapidly maturing cells that are ready to use within 10 days post-revival, in mono- and co-cultures.
Functional
Disease model cells display key phagocytic and cytokine secretion functions.
Disease model cells show a similar proportion of phagocytosis to the genetically matched wild-type control
Disease model cells show a similar degree of phagocytosis of E. coli particles to the genetically matched wild-type control
V7
bit.bio
2024
Prof Roger Pedersen | Adjunct Professor and Senior Research Scientist at Stanford University
Dr Thomas Moreau | Director of Cell Biology Research | bit.bio
Mark Kotter | CEO and founder | bit.bio
Marius Wernig | Professor Departments of Pathology and Chemical and Systems Biology | Stanford University
In this GEN webinar, hear from our distinguished expert, Dr Matthias Pawlowski, and learn about the emerging role of microglia in the pathogenesis of Alzheimer’s disease and their potential as a therapeutic target to treat this disease effectively.